Updated: February 5, 2026

Hyrimoz Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Is Hyrimoz in an Official Drug Shortage in 2026?
The Real Story: Why Patients Are Still Struggling
The Formulary Disruption of 2024–2025
A Timeline of Hyrimoz and the Adalimumab Biosimilar Market
What This Means for You as a Patient
Immediate Steps If You Can't Fill Your Prescription
Don't Miss Doses While You Sort This Out

Is Hyrimoz in a shortage in 2026? Here's the latest on Hyrimoz availability, what's causing access issues, and what patients can do right now.

Patients prescribed Hyrimoz (adalimumab-adaz) are right to ask whether a shortage is affecting their prescription. Here is the most up-to-date picture of Hyrimoz availability in 2026 — what's officially happening, what's causing practical access problems, and what you can do to protect your supply.

Is Hyrimoz in an Official Drug Shortage in 2026?

No. As of early 2026, Hyrimoz (adalimumab-adaz) is not listed on the FDA drug shortage database or the ASHP drug shortage list. Sandoz Inc. continues to manufacture and distribute Hyrimoz in the United States.

However, in January 2026, the FDA database did note that several specific low-concentration Hyrimoz formulations (certain NDC numbers) are being discontinued by Sandoz. The FDA notes that "equivalent Sandoz format is available" — meaning Sandoz is consolidating its product line, not withdrawing the drug. Patients who were prescribed a low-concentration presentation may need to work with their doctor and specialty pharmacy to transition to the equivalent high-concentration citrate-free formulation.

The Real Story: Why Patients Are Still Struggling

Even without a formal shortage, patients nationwide are reporting difficulty filling Hyrimoz on time. The reasons have more to do with the complex adalimumab market than with manufacturing problems:

The Formulary Disruption of 2024–2025

In April 2024, CVS Caremark removed brand-name Humira from its preferred formularies in favor of Hyrimoz and the Cordavis private-label version. This caused a massive and rapid shift in prescribing patterns — within months, the majority of CVS Caremark's adalimumab patients were moved to Hyrimoz or its unbranded equivalent.

Express Scripts and Optum Rx followed with their own preferred biosimilar changes — but they chose different products (Cyltezo for Express Scripts, Nuvaila for Optum). This created a fragmented market where which biosimilar you can access depends entirely on which PBM manages your pharmacy benefits.

A Timeline of Hyrimoz and the Adalimumab Biosimilar Market

October 2018: FDA approves Hyrimoz (adalimumab-adaz) — the third adalimumab biosimilar approval

March 2023: FDA approves Hyrimoz high-concentration citrate-free formulation (100 mg/mL)

July 1, 2023: Hyrimoz launches in the U.S. alongside multiple other adalimumab biosimilars

Late 2023: CVS Health launches Cordavis subsidiary to co-market a private-label version of Hyrimoz at lower list prices

April 2024: CVS Caremark removes Humira from preferred formularies; Hyrimoz becomes the #1 preferred adalimumab product on CVS formularies

2024–2025: Biosimilar adalimumab market share climbs rapidly; by August 2024, CVS had converted 97% of commercial Humira patients to biosimilars

2025: FDA grants Hyrimoz interchangeable status across all relevant strengths; market continues to mature

January 2026: Sandoz begins discontinuing specific low-concentration NDCs; equivalent high-concentration formats remain available

What This Means for You as a Patient

If you take Hyrimoz, here's what you need to know for 2026:

The drug is being manufactured. There is no production shortage.

If you were on a low-concentration formulation that is being discontinued, talk to your doctor about switching to the equivalent high-concentration citrate-free version. The dosing is the same — the injection is just smaller.

Access problems are more likely to come from insurance changes, prior authorization delays, or specialty pharmacy logistics than from any true drug shortage.

If your plan has changed its preferred biosimilar, ask your doctor whether switching makes sense — or request a medical exception to keep Hyrimoz.

Immediate Steps If You Can't Fill Your Prescription

Call your doctor's office and explain the situation. Ask them to check your prior authorization status and help navigate your specialty pharmacy.

Contact Sandoz One Source at 1-833-497-4669 for patient support, insurance assistance, and copay program enrollment.

Ask your pharmacist about interchangeable biosimilars that your insurance covers and that are currently in stock.

Use medfinder to find pharmacies near you that have Hyrimoz or an alternative in stock.

Don't Miss Doses While You Sort This Out

If your condition requires ongoing adalimumab therapy, missing doses can trigger disease flares. Talk to your doctor about whether a brief gap is safe, and explore available alternatives to Hyrimoz if needed. Planning your refills 2–3 weeks in advance is the single best way to avoid gaps in therapy.

Frequently Asked Questions

Yes. Hyrimoz (adalimumab-adaz) is still being manufactured and distributed by Sandoz Inc. in 2026. It is not on the FDA or ASHP drug shortage lists. Sandoz did discontinue some specific low-concentration formulations (certain NDC numbers) in January 2026, but equivalent high-concentration citrate-free formats remain available.

Sandoz is consolidating its Hyrimoz product line. The company noted that equivalent formats are available — specifically the high-concentration citrate-free formulation (100 mg/mL). This is actually a clinically preferred formulation for most patients since it delivers the same dose in a smaller injection volume and is citrate-free, making injections less painful for many patients.

Starting in April 2024, major pharmacy benefit managers (PBMs) began removing brand-name Humira from their preferred drug formularies and replacing it with lower-cost biosimilars like Hyrimoz. By August 2024, CVS Caremark had converted 97% of its commercial Humira patients to biosimilars. Hyrimoz is clinically equivalent to Humira and FDA-approved for the same conditions — the switch is primarily cost-driven.

Call your insurance plan's member services line or log into your insurance portal to check the current formulary status of Hyrimoz (adalimumab-adaz). Ask whether prior authorization is required, which tier the drug is on, and which specialty pharmacy is in-network for this medication. Changes often go into effect January 1 of each year.

Both are adalimumab-adaz manufactured by Sandoz. Cordavis is a CVS Health subsidiary that distributes a private-label, unbranded version at a lower list price — approximately $1,300 to $1,900 per month compared to $3,500 to $6,500 per month for branded Hyrimoz. Medically, they are identical. Your insurance plan will determine which one you receive.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards